|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pathophysiology of atopic dermatitis 显示文摘 | Kang K Stevens SR | 2003 | Clin Dermatol2003，21，： | 1 |
| 2 | Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvu- lar atrial fibrillation: validation of the R2CHADS2 Index in the ROCKET AF ( Rivaroxaban Once-daily, oral, direct factor Xa inhi- bition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagu- lation and Risk factors In Atrial fibrillation) Study Cohorts显示文摘 | Piceini JP Stevens SR Chang YC | 2013 | Cir- culation2013，127，2： | 1 |
| 3 | Rivaroxaban corn pared previous stroke or transient ischaemic attack,,a subgroup a- nalysis of ROCKET AF显示文摘 | Hankey GJ Patel MR Stevens SR | 2012 | Lancet Neurol2012，11，4： | 1 |
| 4 | A simple clinical scoring system to improve the sensitivity and standardization of the diagnosis of mycosis fungoides type cutaneous T-cell lymphoma:logistie re- gression of clinical and laboratory data 显示文摘 | Stevens SR Ke MS Birol A | 2003 | Br J Dermatol2003，149，3： | 1 |
| 5 | Nitric oxide en- hances aggreean degradation by aggrecanase in response to TNF - al- pha but not IL - 1 beta treatment at a post - transcriptional level in bovine cartilage explants 显示文摘 | Stevens AL Wheeler CA Tannenbaum SR | 2008 | Osteoarthritis Cartilage2008，4，： | 1 |
| 6 | Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation:validation of the R(2)CHADS(2)index in the ROCKET AF(Rivaroxaban Once-daily,oral,direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation)and ATRIA(An Ticoagulation and Risk factors In Atrial fibrillation)study cohorts显示文摘 | Piccini JP Stevens SR Chang Y | 2013 | Circulation2013，127，2： | 1 |
| 7 | Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: val- idation of the R(2 )CHADS(2 ) index in the ROCKET AF (Rivaroxaban Once- daily Oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (An- Tieoagulation and Risk factors in Atrial Fibrillation) study cohorts 显示文摘 | Piccini JP Stevens SR Chang Y | 2013 | Circula- tion2013，127，2： | 1 |
| 8 | Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2) CHADS( 2) index in the ROCKET AF (Rivaroxaban Oncedaily Oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA ( AnTicoagulation and Risk factors in Atrial Fibrillation) study cohorts显示文摘 | Piccini JP Stevens SR Chang Y | 2013 | Circulation2013，127，22： | 1 |
| 9 | Essential fatty acid metabolism in boys with attentiondeficit hyperactivity disorder Acids显示文摘 | Stevens LJ Zentall SS Deck JL Abate ML Watkins BA Lipp SR | 1995 | Am J Clin Nutr1995，62，4： | 1 |
| 10 | Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial显示文摘 | Piccini JP Stevens SR Lokhnygina Y | 2013 | J Am Coll Cardiol2013，61，19： | 1 |
| 11 | Pattern of liver enzyme elevations in acute ST-elevation myocardial infarction显示文摘 | Lofthus DM Stevens SR Armstrong PW | 2012 | Coron Artery Dis2012，23，1： | 1 |
| 12 | A simple clinical scoring systemto improve the sensitivity and standardization of the diagnosis of myco-sis fungoides type cutaneous T-cell lymphoma:logistic regression ofclinical and laboratory data显示文摘 | Stevens SR Ke MS Birol A | 2003 | Br J Dermatol2003，149，3： | 1 |
| 13 | Blood pressure before and after electroconvulsive therapy in hypertensive and nonhypertensive patients 显示文摘 | Albin SM Stevens SR Rasmussen KG | 2007 | J ECT2007，23，1： | 1 |
| 14 | Temozolomide:a review of its discovery,chemical properties,pre-clinical development and clinical trials显示文摘 | Newlands es Stevens MF Wedge SR | 1997 | Cancer Treat Rev1997，23，： | 1 |
| 15 | Temozolomide:a review of its discovery,chemical properties,pre-clinical development and clinical trials显示文摘 | Stevens MFG Wedge SR | 1997 | Cancer Treat Rev1997，23，： | 1 |
| 16 | Temozolomide: areview of its discovery, chemical properties, pre-clinical developmentand clinical trials显示文摘 | Newlands ES Stevens MF Wedge SR | 1997 | Cancer Treat Rev1997，23，1： | 1 |
| 17 | Risk factors for mortality after surgery in patiens with cirrhosis显示文摘 | Teh SH Nagorney DM Stevens SR | 2007 | Gastroenterology2007，132，4： | 1 |
| 18 | Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKETAF显示文摘 | HANKEY GJ PATEL MR STEVENS SR | 2012 | Lancet Neurol2012，11，4： | 1 |
| 19 | Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: subgroup analysis of rochet AF显示文摘 | Hankey G J Patel MR Stevens SR | 2012 | Lancet Neurol2012，11，4： | 1 |
| 20 | Nitric oxide enhances aggrecan degradation by aggrecanase in re- sponse to TNF-alpha but not IL-lbeta treatment at a post- transcriptional level in bovine cartilage explants 显示文摘 | Stevens AL Wheeler CA Tannenbaum SR | 2008 | Oste-oarthritis Cartilage2008，16，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员